M&A Deal Summary

Organon Acquires Dermavant Sciences

On September 18, 2024, Organon acquired medical products company Dermavant Sciences from Roivant Sciences for 1.2B USD

Acquisition Highlights
  • This is Organon’s 2nd transaction in the Medical Products sector.
  • This is Organon’s largest (disclosed) transaction.
  • This is Organon’s 2nd transaction in the United States.
  • This is Organon’s 2nd transaction in California.

M&A Deal Summary
Date 2024-09-18
Target Dermavant Sciences
Sector Medical Products
Buyer(s) Organon
Sellers(s) Roivant Sciences
Deal Type Add-on Acquisition
Deal Value 1.2B USD

Target

Dermavant Sciences

Long Beach, California, United States
Dermavant Sciences is focused on developing and commercializing innovative therapeutics in immuno-dermatology. Dermavant Science’s medical dermatology pipeline includes earlier-development, late-stage, and commercialized, product candidates that target specific unmet needs in growing immuno-dermatology markets, plaque psoriasis and atopic dermatitis, as well as other immunological and inflammatory diseases. Dermavant Sciences was founded in 2015 and is based in Long Beach, California.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Organon

Jersey City, New Jersey, United States
Category Company
Sector Healthcare Services
Revenue 6.3B USD (2023)
DESCRIPTION

Organon develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health. Organon is based in Jersey City, New Jersey.

DEAL STATS #
Overall 3 of 3
Sector (Medical Products) 2 of 2
Type (Add-on Acquisition) 3 of 3
State (California) 2 of 2
Country (United States) 2 of 2
Year (2024) 1 of 1
Size (of disclosed) 1 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-11-11 Forendo Pharma

Turku, Finland

Forendo Pharma is a clinical-stage drug development company focused on novel treatments in women’s health. Forendo Pharma is based in Turku, Finland.

Buy $75M

Seller(S) 1

SELLER

Roivant Sciences

London, United Kingdom
Category Company
Founded 2014
Sector Life Science
Employees908
Revenue 125M USD (2024)
DESCRIPTION

Roivant Sciences develops transformative medicines faster by building technologies and developing talent in creative ways, leveraging the Roivant platform to launch Vants – nimble and focused biopharmaceutical and health technology companies. Roivant Sciences was founded in 2014 and is based in London, United Kingdom.

DEAL STATS #
Overall 2 of 2
Sector (Medical Products) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (California) 1 of 1
Country (United States) 2 of 2
Year (2024) 1 of 1
Size (of disclosed) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2023-10-23 Telavant

New York, New York, United States

Telavant is the developer of RVT-3101, a novel TL1A directed antibody. RVT-3101 is a therapy in development for people suffering from inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. Telavant is based in New York, New York.

Sell $7.1B
Mergr

Product

Company

Legal